5-FLUORO-2 DEOSSI-URIDINA (FUDR) IN INFUSIONE CONTINUA CON RITMI CRONOBIOLOGICI CIRCADIANI NEI TUMORI DEL RENE METASTATICI E LOCALMENTE AVANZATI (N+ E/O V+)

Translated title of the contribution: Continuous infusion of 5-fluoro-2-deoxy-uridine (FUDR) with circadian chronobiologic rhythm in locally advanced metastatic renal tumor (N+ e/o V+)

G. Conti, S. Cappoli, E. Gianneo, G. C. Comeri, L. Frigerio, A. Marchiano, B. Damascelli

Research output: Contribution to journalArticle

Abstract

Circadian continuous venous infusion of 5-fluoro-2-deoxy-uridine (PUDR) has been used to treat 134 metastatic renal cell carcinomas (RCC) and 14 locally advanced BCC (all N+). All patients underwent radical nephrectomy and did not receive previous chemo- or radiation therapy. The drug was delivered by the Medtronic Synchromed implantable system with the Hrushesky circadian chronobiologic pattern (14-day cycles of CHT alternating with 14-day intervals of heparinized physiologic saline infusion). The minimum follow-up was 6 months, with a range of 6-48 months and a median of 24 months. The range of treatment was between 3 and 36 months. Results showed 58 progressions (43.2%), 11 mixed responses (8.2%), 17 partial responses (12.7%), 8 complete responses (6%) and 40 stable disease (29.9%). The survival rate is about 40% at 1 year and 18% at 2 years. No toxicity was observed in 112 patients (83.6%), mild in 22 patients (16.4%) and severe (lung fibrosis) in 2 patients (1.5%). In the group of locally advanced RCC all patients are disease-free at a mean follow-up of 15 months (range 6-24 months).

Original languageItalian
Pages (from-to)165-167
Number of pages3
JournalActa Urologica Italica
Volume6
Issue numberSUPPL. 6
Publication statusPublished - 1992

Fingerprint

Floxuridine
Circadian Rhythm
Kidney
Neoplasms
Renal Cell Carcinoma
Nephrectomy
Fibrosis
Radiotherapy
Survival Rate
Lung
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Urology

Cite this

5-FLUORO-2 DEOSSI-URIDINA (FUDR) IN INFUSIONE CONTINUA CON RITMI CRONOBIOLOGICI CIRCADIANI NEI TUMORI DEL RENE METASTATICI E LOCALMENTE AVANZATI (N+ E/O V+). / Conti, G.; Cappoli, S.; Gianneo, E.; Comeri, G. C.; Frigerio, L.; Marchiano, A.; Damascelli, B.

In: Acta Urologica Italica, Vol. 6, No. SUPPL. 6, 1992, p. 165-167.

Research output: Contribution to journalArticle

Conti, G. ; Cappoli, S. ; Gianneo, E. ; Comeri, G. C. ; Frigerio, L. ; Marchiano, A. ; Damascelli, B. / 5-FLUORO-2 DEOSSI-URIDINA (FUDR) IN INFUSIONE CONTINUA CON RITMI CRONOBIOLOGICI CIRCADIANI NEI TUMORI DEL RENE METASTATICI E LOCALMENTE AVANZATI (N+ E/O V+). In: Acta Urologica Italica. 1992 ; Vol. 6, No. SUPPL. 6. pp. 165-167.
@article{a71b34d319c14a099445a19e4705bff6,
title = "5-FLUORO-2 DEOSSI-URIDINA (FUDR) IN INFUSIONE CONTINUA CON RITMI CRONOBIOLOGICI CIRCADIANI NEI TUMORI DEL RENE METASTATICI E LOCALMENTE AVANZATI (N+ E/O V+)",
abstract = "Circadian continuous venous infusion of 5-fluoro-2-deoxy-uridine (PUDR) has been used to treat 134 metastatic renal cell carcinomas (RCC) and 14 locally advanced BCC (all N+). All patients underwent radical nephrectomy and did not receive previous chemo- or radiation therapy. The drug was delivered by the Medtronic Synchromed implantable system with the Hrushesky circadian chronobiologic pattern (14-day cycles of CHT alternating with 14-day intervals of heparinized physiologic saline infusion). The minimum follow-up was 6 months, with a range of 6-48 months and a median of 24 months. The range of treatment was between 3 and 36 months. Results showed 58 progressions (43.2{\%}), 11 mixed responses (8.2{\%}), 17 partial responses (12.7{\%}), 8 complete responses (6{\%}) and 40 stable disease (29.9{\%}). The survival rate is about 40{\%} at 1 year and 18{\%} at 2 years. No toxicity was observed in 112 patients (83.6{\%}), mild in 22 patients (16.4{\%}) and severe (lung fibrosis) in 2 patients (1.5{\%}). In the group of locally advanced RCC all patients are disease-free at a mean follow-up of 15 months (range 6-24 months).",
keywords = "chemotherapy, floxuridine, renal cell carcinoma",
author = "G. Conti and S. Cappoli and E. Gianneo and Comeri, {G. C.} and L. Frigerio and A. Marchiano and B. Damascelli",
year = "1992",
language = "Italian",
volume = "6",
pages = "165--167",
journal = "Acta Urologica Italica",
issn = "0394-2511",
publisher = "S. Karger AG",
number = "SUPPL. 6",

}

TY - JOUR

T1 - 5-FLUORO-2 DEOSSI-URIDINA (FUDR) IN INFUSIONE CONTINUA CON RITMI CRONOBIOLOGICI CIRCADIANI NEI TUMORI DEL RENE METASTATICI E LOCALMENTE AVANZATI (N+ E/O V+)

AU - Conti, G.

AU - Cappoli, S.

AU - Gianneo, E.

AU - Comeri, G. C.

AU - Frigerio, L.

AU - Marchiano, A.

AU - Damascelli, B.

PY - 1992

Y1 - 1992

N2 - Circadian continuous venous infusion of 5-fluoro-2-deoxy-uridine (PUDR) has been used to treat 134 metastatic renal cell carcinomas (RCC) and 14 locally advanced BCC (all N+). All patients underwent radical nephrectomy and did not receive previous chemo- or radiation therapy. The drug was delivered by the Medtronic Synchromed implantable system with the Hrushesky circadian chronobiologic pattern (14-day cycles of CHT alternating with 14-day intervals of heparinized physiologic saline infusion). The minimum follow-up was 6 months, with a range of 6-48 months and a median of 24 months. The range of treatment was between 3 and 36 months. Results showed 58 progressions (43.2%), 11 mixed responses (8.2%), 17 partial responses (12.7%), 8 complete responses (6%) and 40 stable disease (29.9%). The survival rate is about 40% at 1 year and 18% at 2 years. No toxicity was observed in 112 patients (83.6%), mild in 22 patients (16.4%) and severe (lung fibrosis) in 2 patients (1.5%). In the group of locally advanced RCC all patients are disease-free at a mean follow-up of 15 months (range 6-24 months).

AB - Circadian continuous venous infusion of 5-fluoro-2-deoxy-uridine (PUDR) has been used to treat 134 metastatic renal cell carcinomas (RCC) and 14 locally advanced BCC (all N+). All patients underwent radical nephrectomy and did not receive previous chemo- or radiation therapy. The drug was delivered by the Medtronic Synchromed implantable system with the Hrushesky circadian chronobiologic pattern (14-day cycles of CHT alternating with 14-day intervals of heparinized physiologic saline infusion). The minimum follow-up was 6 months, with a range of 6-48 months and a median of 24 months. The range of treatment was between 3 and 36 months. Results showed 58 progressions (43.2%), 11 mixed responses (8.2%), 17 partial responses (12.7%), 8 complete responses (6%) and 40 stable disease (29.9%). The survival rate is about 40% at 1 year and 18% at 2 years. No toxicity was observed in 112 patients (83.6%), mild in 22 patients (16.4%) and severe (lung fibrosis) in 2 patients (1.5%). In the group of locally advanced RCC all patients are disease-free at a mean follow-up of 15 months (range 6-24 months).

KW - chemotherapy

KW - floxuridine

KW - renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0026958212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026958212&partnerID=8YFLogxK

M3 - Articolo

VL - 6

SP - 165

EP - 167

JO - Acta Urologica Italica

JF - Acta Urologica Italica

SN - 0394-2511

IS - SUPPL. 6

ER -